Merrimack zero for 3 as it dumps cancer drug over safety fears, axes staffers (again)

Merrimack is dumping another cancer therapy after a recent trial flagged adverse event worries, leading the biotech to swing the ax across its already severely depleted workforce as it gives up on its third and final clinical shot on goal.